Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies
R. Buhl, E. Derom, G. Ferguson, F. Maltais, E. Pizzichini, J. Reid, H. Watz, L. Groenke, A. Hamilton, K. Tetzlaff, L. Korducki, H. Huisman, S. Waitere-Wijker, E. Bateman (Mainz, Grosshansdorf, Ingelheim, Tübingen, Germany; Ghent, Belgium; Livonia, Ridgefield, United States Of America; Québec, Burlington, Canada; Santa Catarina, Brazil; Dunedin, New Zealand; Alkmaar, Netherlands; Cape Town, South Africa)
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Session: Bronchodilators for asthma and COPD
Session type: Oral Presentation
Number: 1895
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Buhl, E. Derom, G. Ferguson, F. Maltais, E. Pizzichini, J. Reid, H. Watz, L. Groenke, A. Hamilton, K. Tetzlaff, L. Korducki, H. Huisman, S. Waitere-Wijker, E. Bateman (Mainz, Grosshansdorf, Ingelheim, Tübingen, Germany; Ghent, Belgium; Livonia, Ridgefield, United States Of America; Québec, Burlington, Canada; Santa Catarina, Brazil; Dunedin, New Zealand; Alkmaar, Netherlands; Cape Town, South Africa). Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies. Eur Respir J 2014; 44: Suppl. 58, 1895
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: